Skin Cancer Market Growing Rapidly in Asia Pacific Region till 2023; Moberg Pharma AB, Boehringer Ingelheim GmbH, Meda AB, iCAD Inc. and More

The Asia Pacific Skin Cancer Market is expected to grow at a CAGR of 8.8% during forecasted period.

Cancer is becoming one of the major problems across the globe. Different types of cancer are been registered around the globe, but skin cancer is considered as one of the most common types of cancer. Over 90% of skin cancer caused due to exposure to ultraviolet radiation from the sun. These ultraviolet radiations are increasing continuously due to reducing ozone level.

There are three major types of skin cancer namely basal cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. Exposure to the radiation during childhood can cause melanomas and basal-cell cancers. People with light skin are more susceptible to the skin cancer.

Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/1173 .

The Asia Pacific skin cancer market is driven by increasing prevalence of skin cancer, the presence of developing economies and increasing government support. Australia accounts for the largest market share owing to a huge number of a patient having skin cancer. While adverse effect associated with the treatment, long approval time for the drugs, and strict regulatory policies may restrain the growth of the market over the corresponding period.

Key Players

Some of key the players in the market are F. Hoffmann-la Roche Ltd. (Switzerland), Novartis International AG (Switzerland), Sun Pharma Industries Ltd. (India), Elekta AB (Sweden), Varian Medical Systems Inc. (US), Cannabis Science Inc. (US), Cellceutix Corp. (US), LEO Pharma A/S (Denmark), Moberg Pharma AB (Sweden), Mylan Pharmaceutical Inc. (US), Oncothyreon Inc. (US), Eli Lilly and Co. (US), Bristol Myers Squibb Co. (US), Boehringer Ingelheim GmbH (Germany), Aqua Pharmaceuticals LLC (US), Valeant Pharmaceuticals Inc (Canada), Meda AB (US), iCAD Inc. (Sweden), and Merck & Co. Inc. (US).

Regional Analysis

Australia dominates the Asia Pacific skin cancer market owing to exposure to UV radiation in sunlight, extensive use of commercial solariums, believe in tanning skin. According to Cancer Council Australia, Approximately, two in three Australians are likely to diagnose with skin cancer by the time they are 70 years old. Additionally above 750,000 people treated with skin cancer every year.

Japan accounts for the second largest market, where 20-25 cases of every 100,000 people are diagnosed with skin cancer. China is the third largest market due to huge population base, rapidly changing the economy, and increasing healthcare expenditure. The incidence of skin cancer in China per 100,000 population is 11-12 cases.

Countries like India, Republic of Korea, and rest of the Asia Pacific also showing significant growth in the skin cancer cases owing to increasing ultraviolet radiation from the sun.

Get Attarctive Discount @ https://www.marketresearchfuture.com/check-discount/1173 .

Brief TOC

Introduction
Research Methodology
Market Dynamics
Market Factor Analysis
Asia-Pacific Skin Cancer Market, By Type
Asia-Pacific Skin Cancer Market, By Treatment
Asia-Pacific Skin Cancer Market, By End User
Asia-Pacific Skin Cancer Market, By Region
Competitive Landscape
Company Profile

…TOC COntinued

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.